High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study
Dana-Farber Cancer Institute · with Stahl Family Charitable Foundation, The Childhood Brain Tumor Foundation · NCT05740839
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 30
- US sites recruiting
- 1
- Study start
- December 4, 2023
- Record last updated
- February 24, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors.
The names of the study interventions involved in this study are/is:
- High-Intensity Interval Training (HIIT)
Being studied: HIIT Exercise Program; Control Group
Conditions: Pediatric Brain Tumor
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Written informed consent prior to any study-related procedures.
- At time of study are a young adult, aged 18-45 years.
- Histologically diagnosed brain tumor during childhood, or currently diagnosed with an IDH-mutant glioma (diagnosed > 18 years).
- Are at least 2 years post tumor-directed therapy for pediatric brain tumor survivors, or at least 1 year since their most recent surgery, radiation or chemotherapy treatment for IDH-mutant glioma patients (or are deemed able to participate in the study based on the assessment of their treating physician). IDH-mutant glioma patients can participate while on maintenance therapy with an IDH inhibitor.
- The effects of exercise on the developing fetus are unknown. For this reason, people of child-bearing potential must verify pregnancy status by providing first day of their last menstrual cycle and agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry. Should a person become pregnant or suspect that they are pregnant while participating on the trial, they should inform their treating physician immediately.
- Medically cleared to participate in exercise by their referring physician or a certified clinical exercise physiologist.
- If participants have a diagnosis of tumor-related epilepsy, they must have good seizure control, with no generalized seizures in the 6 months preceding enrollment.
- Are without any other medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases.
- Speak English and/or Spanish.
- Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week.
- Does not smoke cigarettes or e-cigarettes (no smoking during the previous 12 months). Those who infrequently smoke in social settings will be included. Those who vape will also be included.
- Willing to travel to DFCI for necessary data collection.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
- Diagnosis of primary spinal cord tumor.
- Pre-existing medical conditions such as uncontrolled tumor-related epilepsy, cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise.
- Patients with evidence of progressive CNS or systemic cancer in the last 3 months.
- People who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
- Actively on a weight loss diet.
- Participate in more than 60 minutes of moderate or vigorous structured exercise/week.
- Currently and regularly smokes.
- Unable to travel to DFCI for necessary data collection.
- May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.
Recruiting US locations
Dana Farber Cancer Institute
Boston, MA 02215
Site contact: Christina M Dieli-Conwright, PhD, MPH · 617-632-3800 · ChristinaM_Dieli-Conwright@dfci.harvard.edu
Study contacts (from the official record)
- Christina Dieli-Conwright, PhD, MPH · 617-582-8321 · ChristinaM_Dieli-Conwright@dfci.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+